D'Orléans-Juste P, Télémaque S, Claing A, Ihara M, Yano M
Department of Pharmacology, Medical School, Université de Sherbrooke, Québec, Canada.
Br J Pharmacol. 1992 Apr;105(4):773-5. doi: 10.1111/j.1476-5381.1992.tb09055.x.
Although ET1 and ET2 binding sites were found in rat lung membranes, a selective ET1 receptor antagonist, BQ-123 (10 microM), did not displace [125I]-endothelin-1 ([125I]ET-1) from ET2 sites, illustrating the selectivity of the angatonist for ET1 receptors. In rat perfused lungs, BQ-123 (1 microM) markedly reduced the prostacyclin (PGI2) releasing properties of endothelin-1 (ET-1: 5 nM) and human big-ET-1 (100 nM) suggesting that both peptides induce the release of PGI2 via the selective activation of ET1 receptors.
尽管在大鼠肺膜中发现了ET1和ET2结合位点,但选择性ET1受体拮抗剂BQ - 123(10微摩尔)并未从ET2位点取代[125I] - 内皮素 - 1([125I]ET - 1),这说明了该拮抗剂对ET1受体的选择性。在大鼠灌注肺中,BQ - 123(1微摩尔)显著降低了内皮素 - 1(ET - 1:5纳摩尔)和人big - ET - 1(100纳摩尔)的前列环素(PGI2)释放特性,这表明这两种肽均通过选择性激活ET1受体诱导PGI2的释放。